Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges

Luis M. Seijo, Nir Peled, Daniel Ajona, Mattia Boeri, John K. Field, Gabriella Sozzi, Ruben Pio, Javier J. Zulueta, Avrum Spira, Pierre P. Massion, Peter J. Mazzone, Luis M. Montuenga

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

The present review is an update of the research and development efforts regarding the use of molecular biomarkers in the lung cancer screening setting. The two main unmet clinical needs, namely, the refinement of risk to improve the selection of individuals undergoing screening and the characterization of undetermined nodules found during the computed tomography–based screening process are the object of the biomarkers described in the present review. We first propose some principles to optimize lung cancer biomarker discovery projects. Then, we summarize the discovery and developmental status of currently promising molecular candidates, such as autoantibodies, complement fragments, microRNAs, circulating tumor DNA, DNA methylation, blood protein profiling, or RNA airway or nasal signatures. We also mention other emerging biomarkers or new technologies to follow, such as exhaled breath biomarkers, metabolomics, sputum cell imaging, genetic predisposition studies, and the integration of next-generation sequencing into study of circulating DNA. We also underline the importance of integrating different molecular technologies together with imaging, radiomics, and artificial intelligence. We list a number of completed, ongoing, or planned trials to show the clinical utility of molecular biomarkers. Finally, we comment on future research challenges in the field of biomarkers in the context of lung cancer screening and propose a design of a trial to test the clinical utility of one or several candidate biomarkers.

Original languageEnglish
Pages (from-to)343-357
Number of pages15
JournalJournal of Thoracic Oncology
Volume14
Issue number3
DOIs
Publication statusPublished - Mar 2019

Fingerprint

Early Detection of Cancer
Lung Neoplasms
Biomarkers
Technology
Metabolomics
Artificial Intelligence
DNA
DNA Methylation
Genetic Predisposition to Disease
Tumor Biomarkers
Sputum
MicroRNAs
Nose
Autoantibodies
Blood Proteins
RNA
Research
Neoplasms

Keywords

  • Biomarkers
  • Clinical utility
  • Lung cancer
  • Screening
  • Test validation
  • Trial design

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Biomarkers in Lung Cancer Screening : Achievements, Promises, and Challenges. / Seijo, Luis M.; Peled, Nir; Ajona, Daniel; Boeri, Mattia; Field, John K.; Sozzi, Gabriella; Pio, Ruben; Zulueta, Javier J.; Spira, Avrum; Massion, Pierre P.; Mazzone, Peter J.; Montuenga, Luis M.

In: Journal of Thoracic Oncology, Vol. 14, No. 3, 03.2019, p. 343-357.

Research output: Contribution to journalReview article

Seijo, LM, Peled, N, Ajona, D, Boeri, M, Field, JK, Sozzi, G, Pio, R, Zulueta, JJ, Spira, A, Massion, PP, Mazzone, PJ & Montuenga, LM 2019, 'Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges', Journal of Thoracic Oncology, vol. 14, no. 3, pp. 343-357. https://doi.org/10.1016/j.jtho.2018.11.023
Seijo, Luis M. ; Peled, Nir ; Ajona, Daniel ; Boeri, Mattia ; Field, John K. ; Sozzi, Gabriella ; Pio, Ruben ; Zulueta, Javier J. ; Spira, Avrum ; Massion, Pierre P. ; Mazzone, Peter J. ; Montuenga, Luis M. / Biomarkers in Lung Cancer Screening : Achievements, Promises, and Challenges. In: Journal of Thoracic Oncology. 2019 ; Vol. 14, No. 3. pp. 343-357.
@article{f5086c420bd048c18873cc3dd79ff905,
title = "Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges",
abstract = "The present review is an update of the research and development efforts regarding the use of molecular biomarkers in the lung cancer screening setting. The two main unmet clinical needs, namely, the refinement of risk to improve the selection of individuals undergoing screening and the characterization of undetermined nodules found during the computed tomography–based screening process are the object of the biomarkers described in the present review. We first propose some principles to optimize lung cancer biomarker discovery projects. Then, we summarize the discovery and developmental status of currently promising molecular candidates, such as autoantibodies, complement fragments, microRNAs, circulating tumor DNA, DNA methylation, blood protein profiling, or RNA airway or nasal signatures. We also mention other emerging biomarkers or new technologies to follow, such as exhaled breath biomarkers, metabolomics, sputum cell imaging, genetic predisposition studies, and the integration of next-generation sequencing into study of circulating DNA. We also underline the importance of integrating different molecular technologies together with imaging, radiomics, and artificial intelligence. We list a number of completed, ongoing, or planned trials to show the clinical utility of molecular biomarkers. Finally, we comment on future research challenges in the field of biomarkers in the context of lung cancer screening and propose a design of a trial to test the clinical utility of one or several candidate biomarkers.",
keywords = "Biomarkers, Clinical utility, Lung cancer, Screening, Test validation, Trial design",
author = "Seijo, {Luis M.} and Nir Peled and Daniel Ajona and Mattia Boeri and Field, {John K.} and Gabriella Sozzi and Ruben Pio and Zulueta, {Javier J.} and Avrum Spira and Massion, {Pierre P.} and Mazzone, {Peter J.} and Montuenga, {Luis M.}",
year = "2019",
month = "3",
doi = "10.1016/j.jtho.2018.11.023",
language = "English",
volume = "14",
pages = "343--357",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Biomarkers in Lung Cancer Screening

T2 - Achievements, Promises, and Challenges

AU - Seijo, Luis M.

AU - Peled, Nir

AU - Ajona, Daniel

AU - Boeri, Mattia

AU - Field, John K.

AU - Sozzi, Gabriella

AU - Pio, Ruben

AU - Zulueta, Javier J.

AU - Spira, Avrum

AU - Massion, Pierre P.

AU - Mazzone, Peter J.

AU - Montuenga, Luis M.

PY - 2019/3

Y1 - 2019/3

N2 - The present review is an update of the research and development efforts regarding the use of molecular biomarkers in the lung cancer screening setting. The two main unmet clinical needs, namely, the refinement of risk to improve the selection of individuals undergoing screening and the characterization of undetermined nodules found during the computed tomography–based screening process are the object of the biomarkers described in the present review. We first propose some principles to optimize lung cancer biomarker discovery projects. Then, we summarize the discovery and developmental status of currently promising molecular candidates, such as autoantibodies, complement fragments, microRNAs, circulating tumor DNA, DNA methylation, blood protein profiling, or RNA airway or nasal signatures. We also mention other emerging biomarkers or new technologies to follow, such as exhaled breath biomarkers, metabolomics, sputum cell imaging, genetic predisposition studies, and the integration of next-generation sequencing into study of circulating DNA. We also underline the importance of integrating different molecular technologies together with imaging, radiomics, and artificial intelligence. We list a number of completed, ongoing, or planned trials to show the clinical utility of molecular biomarkers. Finally, we comment on future research challenges in the field of biomarkers in the context of lung cancer screening and propose a design of a trial to test the clinical utility of one or several candidate biomarkers.

AB - The present review is an update of the research and development efforts regarding the use of molecular biomarkers in the lung cancer screening setting. The two main unmet clinical needs, namely, the refinement of risk to improve the selection of individuals undergoing screening and the characterization of undetermined nodules found during the computed tomography–based screening process are the object of the biomarkers described in the present review. We first propose some principles to optimize lung cancer biomarker discovery projects. Then, we summarize the discovery and developmental status of currently promising molecular candidates, such as autoantibodies, complement fragments, microRNAs, circulating tumor DNA, DNA methylation, blood protein profiling, or RNA airway or nasal signatures. We also mention other emerging biomarkers or new technologies to follow, such as exhaled breath biomarkers, metabolomics, sputum cell imaging, genetic predisposition studies, and the integration of next-generation sequencing into study of circulating DNA. We also underline the importance of integrating different molecular technologies together with imaging, radiomics, and artificial intelligence. We list a number of completed, ongoing, or planned trials to show the clinical utility of molecular biomarkers. Finally, we comment on future research challenges in the field of biomarkers in the context of lung cancer screening and propose a design of a trial to test the clinical utility of one or several candidate biomarkers.

KW - Biomarkers

KW - Clinical utility

KW - Lung cancer

KW - Screening

KW - Test validation

KW - Trial design

UR - http://www.scopus.com/inward/record.url?scp=85060116337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060116337&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2018.11.023

DO - 10.1016/j.jtho.2018.11.023

M3 - Review article

C2 - 30529598

AN - SCOPUS:85060116337

VL - 14

SP - 343

EP - 357

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 3

ER -